Literature DB >> 21908433

Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.

Li Li1, Emily Bailey, Sarah Greenblatt, David Huso, Donald Small.   

Abstract

Clinical evidence has shown that FLT3 internal tandem duplication (ITD) mutation confers poor prognosis in acute myeloid leukemia. Loss of the FLT3 wild-type (WT) allele is associated with even worse prognosis. We have previously reported that heterozygous FLT3(wt/ITD) "knockin" mice develop a slowly fatal myeloproliferative neoplasm (MPN). To study the roles of the WT FLT3 and ITD alleles in the development of MPNs, we generated FLT3/ITD homozygous (FLT3(ITD/ITD)) and hemizygous (FLT3(-/ITD)) mice. FLT3(-/ITD) mice, with the loss of WT allele, display a more severe MPN, as evidenced by even larger spleen, higher white blood cell counts, and shorter survival, compared with FLT3(wt/ITD) mice. Reintroduction of the WT FLT3 allele into FLT3(-/ITD) BM slowed the progression of MPN in recipient mice. FLT3(ITD/ITD) mice had an even severe MPN compared with the FLT3(-/ITD) and FLT3(wt/ITD) mice. Spontaneous leukemia developed in a small fraction of the FLT3(ITD/ITD) mice but was never observed in the FLT3(-/ITD) and FLT3(wt/ITD) mice. Our results suggest that loss of the WT allele contributes to the development of a more severe phenotype. Thus, the WT FLT3 allele seemingly functions as a tumor suppressor, attenuating the function of the FLT3/ITD allele in leukemia harboring FLT3/ITD mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908433      PMCID: PMC3208299          DOI: 10.1182/blood-2011-01-328096

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

Review 1.  Diversification of haematopoietic stem cells to specific lineages.

Authors:  S H Orkin
Journal:  Nat Rev Genet       Date:  2000-10       Impact factor: 53.242

2.  Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells.

Authors:  Clare Heyworth; Stella Pearson; Gillian May; Tariq Enver
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

3.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  FLT3 expression initiates in fully multipotent mouse hematopoietic progenitor cells.

Authors:  Natalija Buza-Vidas; Petter Woll; Anne Hultquist; Sara Duarte; Michael Lutteropp; Tiphaine Bouriez-Jones; Helen Ferry; Sidinh Luc; Sten Eirik Waelgaard Jacobsen
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

5.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity.

Authors:  J Adolfsson; O J Borge; D Bryder; K Theilgaard-Mönch; I Astrand-Grundström; E Sitnicka; Y Sasaki; S E Jacobsen
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

7.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

Authors:  F Hayakawa; M Towatari; H Kiyoi; M Tanimoto; T Kitamura; H Saito; T Naoe
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

8.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Authors:  S P Whitman; K J Archer; L Feng; C Baldus; B Becknell; B D Carlson; A J Carroll; K Mrózek; J W Vardiman; S L George; J E Kolitz; R A Larson; C D Bloomfield; M A Caligiuri
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 9.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

10.  Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

Authors:  Scott C Kogan; Jerrold M Ward; Miriam R Anver; Jules J Berman; Cory Brayton; Robert D Cardiff; John S Carter; Sherri de Coronado; James R Downing; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy Lee Harris; Hiroshi Hiai; Elaine S Jaffe; Ian C M MacLennan; Pier Paolo Pandolfi; Paul K Pattengale; Archibald S Perkins; R Mark Simpson; Mark S Tuttle; Joanne F Wong; Herbert C Morse
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

View more
  24 in total

1.  Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia.

Authors:  Amy L Paguirigan; Jordan Smith; Soheil Meshinchi; Martin Carroll; Carlo Maley; Jerald P Radich
Journal:  Sci Transl Med       Date:  2015-04-01       Impact factor: 17.956

2.  Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Authors:  Alan H Shih; Cem Meydan; Kaitlyn Shank; Francine E Garrett-Bakelman; Patrick S Ward; Andrew M Intlekofer; Abbas Nazir; Eytan M Stein; Kristina Knapp; Jacob Glass; Jeremy Travins; Kim Straley; Camelia Gliser; Christopher E Mason; Katharine Yen; Craig B Thompson; Ari Melnick; Ross L Levine
Journal:  Cancer Discov       Date:  2017-02-13       Impact factor: 39.397

3.  Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.

Authors:  Anne Kresinsky; Reinhard Bauer; Tina M Schnöder; Tobias Berg; Daria Meyer; Volker Ast; Rainer König; Hubert Serve; Florian H Heidel; Frank-D Böhmer; Jörg P Müller
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

4.  Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.

Authors:  N Chatain; R C Perera; G Rossetti; J Rossa; P Carloni; M Schemionek; T Haferlach; T H Brümmendorf; S Schnittger; S Koschmieder
Journal:  Leukemia       Date:  2015-05-27       Impact factor: 11.528

Review 5.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

6.  Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.

Authors:  Manoj Garg; Yasunobu Nagata; Deepika Kanojia; Anand Mayakonda; Kenichi Yoshida; Sreya Haridas Keloth; Zhi Jiang Zang; Yusuke Okuno; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Ling-Wen Ding; Tamara Alpermann; Qiao-Yang Sun; De-Chen Lin; Wenwen Chien; Vikas Madan; Li-Zhen Liu; Kar-Tong Tan; Abhishek Sampath; Subhashree Venkatesan; Koiti Inokuchi; Satoshi Wakita; Hiroki Yamaguchi; Wee Joo Chng; Shirley-Kow Yin Kham; Allen Eng-Juh Yeoh; Masashi Sanada; Joanna Schiller; Karl-Anton Kreuzer; Steven M Kornblau; Hagop M Kantarjian; Torsten Haferlach; Michael Lill; Ming-Chung Kuo; Lee-Yung Shih; Igor-Wolfgang Blau; Olga Blau; Henry Yang; Seishi Ogawa; H Phillip Koeffler
Journal:  Blood       Date:  2015-10-05       Impact factor: 22.113

7.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Authors:  C D DiNardo; I S Tiong; A Quaglieri; S MacRaild; S Loghavi; F C Brown; R Thijssen; G Pomilio; A Ivey; J M Salmon; C Glytsou; S A Fleming; Q Zhang; H Ma; K P Patel; S M Kornblau; Z Xu; C C Chua; Xufeng Chen; P Blombery; C Flensburg; N Cummings; I Aifantis; H Kantarjian; D C S Huang; A W Roberts; I J Majewski; M Konopleva; A H Wei
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

Review 8.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

9.  FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice.

Authors:  Emily Bailey; Li Li; Amy S Duffield; Hayley S Ma; David L Huso; Don Small
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-19       Impact factor: 11.205

10.  Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.

Authors:  Anne Kresinsky; Tina M Schnöder; Ilse D Jacobsen; Martina Rauner; Lorenz C Hofbauer; Volker Ast; Rainer König; Bianca Hoffmann; Carl-Magnus Svensson; Marc Thilo Figge; Ingrid Hilger; Florian H Heidel; Frank- D Böhmer; Jörg P Müller
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.